Q BioMed Inc. Uplisted to OTCQB Market

Nov 13, 2015, 08:30 ET from Q BioMed Inc

NEW YORK, November 13, 2015 /PRNewswire/ --

Q BioMed Inc. (OTCQB: QBIO), today announced that its common stock is being uplisted to the OTCQB effective November 13, 2015.

The OTCQB® Venture Marketplace is for entrepreneurial and development stage U.S. and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. These standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. Investors also have access to Real-Time Level 2 Quotes available on the OTC Markets website http://www.otcmarkets.com.

Denis Corin, CEO of Q BioMed Inc., stated, "We are very pleased with this improvement in the market categorization of our company as we believe it demonstrates our commitment to build a quality public company. Along with our recent engagement of Marcum LLP as our auditors and the recently announced additions to our advisory board, the uplisting is another corporate milestone met in our evolution and execution of our goals as a public company. Our current and future shareholders should all be very pleased with this development. We believe that the OTCQB marketplace will enhance our liquidity and profile within the investing community."

Please visit our website http://www.qbiomed.com and sign up for our news and investor alerts to stay informed of our progress.

About Q BioMed Inc. 

Q BioMed Inc. "Q" is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need‏.

Forward-Looking Statements: 

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.


Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435 


SOURCE Q BioMed Inc